Abstracts tagged "autoantigens"

Abstract Number: 1879 • ACR Convergence 2024
Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
Mario Bautista-Vargas¹, Adrian Romero-Ocampo², Juan José Pino Vélez³, juliana Muñoz-Bedoya⁴ and Diego Rosselli⁵, ¹Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ²Universidad de Antioquia, Medellín – Colombia, Medellin, Antioquia, Colombia, ³Universidad de Antioquia, Envigado, Antioquia, Colombia, ⁴Universidad Corpas, Bogotá, Colombia, ⁵Pontificia Universidad Javeriana, Bogotá, Colombia
Background/Purpose: The implementation of the SISPRO system enables it to function as a tool capable of collecting pertinent health system data. This information is publicly…
Abstract Number: 0009 • ACR Convergence 2024
Comprehensive Autoantibody Profiling Highlights Clinical Relevance of Autoantibodies to G Protein-coupled Receptors in Systemic Sclerosis: Insights from a B-cell Depletion Clinical Trial
Kazuki Matsuda, Shinichi Sato and Ayumi Yoshizaki, The University of Tokyo, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) affects the skin and internal organs with a poor prognosis. While the exact cause remains unclear, increasing evidence indicates that B…
Abstract Number: 2391 • ACR Convergence 2024
Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
Güllü Sandal Uzun¹, Emily Apsley² and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: The anti-nuclear antibody (ANA test) is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
Abstract Number: 0011 • ACR Convergence 2024
Preclinical Manufacturability and Activity of KYV-102 from Patients with Systemic Lupus Erythematosus Using Ingenui-T: A Rapid, Autologous Chimeric Antigen Receptor T-Cell Manufacturing Solution Utilizing Whole Blood
Brandon Kwong¹, Daniel Anaya¹, Soo Park², Sunetra Biswas², Jeevitha Jeevan², Jesus Banuelos², Madison Strobach², Nicole Khoshnoodi¹, Timothy Klasson¹, Santiago Foos-Russ¹, Jennifer Zeng¹, Candice Gibson³, Jazmin Bravo², Simone Sandoval¹, Shouvonik Sengupta¹, Shairaz Shah¹, Tom Van Blarcom² and Karen Walker², ¹Kyverna Therapeutics, Inc., Emeryville, CA, ²Kyverna Therapeutics, Inc., Emeryville, ³Kyverna Therapeutics, Inc., Emerybille
Background/Purpose: Apheresis in conventional chimeric antigen receptor (CAR) T-cell therapy can be burdensome, and conventional manufacturing cultures apheresis-derived cells for 7-14 days, leading to a…
Abstract Number: 2665 • ACR Convergence 2024
Autoantibody Titers Against Specific Epitope Peptides Predict Treatment Resistance in Interstitial Lung Disease Associated with Anti-MDA5 Dermatomyositis
Tsuneo Sasai¹, Ran Nakashima¹, Atsubumi Ogawa², Motohiro Nonaka², Norimichi Nomura², Yasuhiro Nohda², Mirei Shirakashi³, Ryosuke Hiwa², Hideaki Tsuji¹, Shuji Akizuki⁴, Hajime Yoshifuji¹, Tsuneyo Mimori⁵ and Akio Morinobu⁶, ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Kyoto University, Kyoto, Japan, ³Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, ⁴Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto City, Japan, ⁵Takeda Clinic for Rheumatic Diseases, Kyoto, Japan, ⁶Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (DM) is frequently associated with rapidly progressive interstitial lung disease (RP-ILD), leading to poor prognosis. Initial combinational therapy…
Abstract Number: 0032 • ACR Convergence 2024
Increased Expression of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues During the Early Evolution of Collagen-Induced Arthritis
Wenxian Zhou¹, Michael Duryee², Nozima Aripova², Jill Poole², Carlos Hunter², Amy Nelson², Tate Johnson², Daniel Anderson³, Geoffrey Thiele² and Ted Mikuls², ¹University of Nebraska Medical Center, Bellevue, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: The risk of heart failure (HF) is increased in patients with rheumatoid arthritis (RA), although mechanisms of myocardial dysfunction underlying HF development in RA…
Abstract Number: 2667 • ACR Convergence 2024
Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein
Jon Musai¹, Sahana Jayaraman², katherine Pak³, Iago Pinal-Fernandez⁴, Sandra Muñoz-braceras⁵, Maria Casal-Dominguez⁶, Eric Cho⁵, Fa'alataitaua Fitisemanu⁵, jose milisenda⁷, Lisa Rider⁸, Adam Schiffenbauer³, Albert Selva-O’Callaghan⁹, Thomas E Lloyd¹⁰, Lisa Christopher-Stine¹¹, Peter Burbelo¹², Benjamin Larman¹¹ and Andrew Mammen¹³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³National Institutes of Health, Bethesda, MD, ⁴NIAMS/National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁶NIAMS, NIH, Bethesda, MD, ⁷Hospital Clinic de Barcelona, Barcelona, Spain, ⁸NIEHS, NIH, Garrett Park, MD, ⁹Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ¹⁰Johns Hopkins University School of Medicine, Lutherville, MD, ¹¹Johns Hopkins University, Baltimore, MD, ¹²National Institute of Dental and Craniofacial Research, Bethesda, MD, ¹³NIH, Bethesda, MD
Background/Purpose: Many myositis patients have myositis-specific autoantibodies (MSA) that define unique clinical phenotypes. For instance, dermatomyositis (DM) patients with anti-Mi2 autoantibodies have weaker muscles, higher…
Abstract Number: 0033 • ACR Convergence 2024
Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles
Linda Mathsson-Alm¹, Helga Westerlind², Isabel Gehring³, Monika Hansson², Nasim Ghasemzadeh¹, Jessica Rojas-Restrepo³, Saedis Saevarsdottir⁴, Joseph Sexton⁵, Siri Lillegraven⁶, Espen Haavardsholm⁶, Merete Hetland⁷, Hilde Hammer⁸, Tore K. Kvien⁹, Bente Glintborg¹⁰, Leonid Padyukov², Johan Askling² and Caroline Grönwall², and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), ¹Thermo Fisher Scientific, Uppsala, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Thermo Fisher Scientific, Freiburg, Germany, ⁴University of Iceland, Reykjavik, Iceland, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁸Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
Abstract Number: 0039 • ACR Convergence 2024
Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients’ Serum
Lacie Scaletta¹, Teneema Kuriakose¹, Sambit Nanda¹, Mia Collins², Erika Darrah³, Iain McInnes⁴, David Close⁵ and Gary Sims¹, ¹Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ²Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ³Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁵Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) promote inflammation and joint tissue injury and define a poor prognostic group of patients with rheumatoid arthritis (RA). Citrullinated autoantigens…
Abstract Number: 0320 • ACR Convergence 2024
Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis
Iago Pinal-Fernandez¹, Daniel Reay², Timothy Oriss², katherine Pak³, Maria Casal-Dominguez⁴, jose milisenda⁵, Albert Selva-O’Callaghan⁶, Werner Stenzel⁷, Andrew Mammen¹ and Dana Ascherman⁸, ¹NIH, Bethesda, MD, ²University of Pittsburgh School of Medicine, Pittsburgh, PA, ³National Institutes of Health, Bethesda, MD, ⁴NIH, Bathesda, MD, ⁵Hospital Clinic de Barcelona, Barcelona, Spain, ⁶Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁷Charite University, Berlin, Germany, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA
Background/Purpose: Previous work has shown unique gene expression profiles in muscle tissue corresponding to the anti-synthetase syndrome, with an emphasis on interferon gene signatures (Type…
Abstract Number: 0837 • ACR Convergence 2024
Bispecific Autoantigen-T Cell Engagers (BaiTE) to Selectively Target Autoreactive B Cells in Antiphospholipid Syndrome
Yuanxuan Xia¹, Jin Liu¹, Alexander Pearlman¹, Brian Mog¹, Elana Shaw¹, Kyle J. Kaeo¹, Colin Gliech¹, Brock Moritz¹, Tolulope Awosika¹, Sarah DiNapoli¹, Stephanie Glavaris¹, Jiaxin Ge¹, Tushar Nichakawade¹, Nikita Marcou¹, Suman Paul¹, Drew Pardoll¹, Chetan Bettegowda¹, Daniel Goldman², Michelle Petri², Antony Rosen¹, Kenneth W. Kinzler¹, Shibin Zhou¹, Bert Vogelstein¹ and Maximilian F. Konig¹, ¹The Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Available drugs to treat autoimmune diseases are indiscriminate, suppressing self-reactive and protective immune responses alike. This lack of therapeutic precision results in infection and…
Abstract Number: 0892 • ACR Convergence 2024
Peptides from Candidate Sjögren’s Disease Autoantigens and Salivary Gland Tissue-Enriched Proteins Eluted from Human Salivary Gland HLA-DR
Tommi C. Taylor¹, Sri Ramarathinam², Shan Zou Chung², Kirti Pandey², Ananth Aditya Jupudi¹, Bhuwan Khatri³, Sherri Longobardi³, Charmaine Lopez-Davis³, Astrid Rasmussen³, Kiely Grundahl³, Robert Hal Scofield³, Christopher Lessard³, Linda F. Thompson³, Anthony W. Purcell² and A. Darise Farris³, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Monash University, Clayton, Victoria, Australia, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Sjögren’s Disease (SjD) is characterized by aberrant autoimmune reactions in lacrimal and salivary glands (SG) leading to severe dryness. Evidence for B cell help…
Abstract Number: 0923 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues
Kimberley Sinanan¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Jill Poole¹, Carlos Hunter¹, Amy Nelson¹, Tate Johnson¹, Daniel Anderson³, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: Recent studies have highlighted the importance of malondialdehyde-acetaldehyde (MAA)-modified proteins and resulting immune responses in the pathogenesis of rheumatoid arthritis (RA). MAA adducts have…
Abstract Number: 0963 • ACR Convergence 2024
Stratification According to Autoantibody Status in Systemic Sclerosis Reveals Distinct Molecular Signatures
Bénédicte ROUVIERE¹, Christelle Le dantec², Eléonore Bettacchioli³, Lorenzo Beretta⁴, Céline Cao², Christophe Jamin², Jacques-Olivier Pers⁵, Nathan Foulquier², Martin Kerick⁶, Javier Martin⁶, Marta Alarcon-Riquelme⁷, Claire de Moreuil⁸, Divi Cornec³ and Sophie Hillion², and PRECISESADS Clinical Consortium, PRECISESADS Metabolomic Study Group, ¹CHRU de Brest, LBAI. UMR 1227, University of Brest, Brest, France, ²LBAI. UMR 1227, University of Brest, Brest, France, ³Service de Rhumatologie, CHU de Brest, Brest, France, ⁴Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, ⁵University of Brest, Brest, France, ⁶Instituto de Parasitología y Biomedicina 'López-Neyra', CSIC, PTS Granada, Spain, Granada, Spain, ⁷Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁸Service de médecine interne, CHU de Brest, Brest, France
Background/Purpose: Systemic sclerosis is a heterogeneous disease, complicating its management. Its complexity and the insufficiency of clinical manifestations alone to delineate homogeneous patient groups further…
Abstract Number: 1652 • ACR Convergence 2024
Extracellular Vesicles from Lymphocyte B and Neutrophil Presents Ro52, Ro60 and La Autoantigens in Patient Suffering from Sjögren Syndrome
Lily BRUYERE¹, Anne-Claire DUCHEZ², Martin KILLIAN³ and Stéphane PAUL⁴, ¹université jean-monnet, saint-etienne, ²EFS, saint-etienne, ³chu Saint-Etienne, saint-etienne, ⁴CIRI, Saint Etienne, France
Background/Purpose: Extracellular Vesicles (EVs) are double lipid bilayer-enclosed membranous vesicles, produced and discharged from almost all cells. EVs are known for inter-cellular communication by releasing…

1
2
3
…
8
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].